Clinical

Dataset Information

0

TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trial


ABSTRACT: Interventions: TAS-102: 35mg/m2 given orally twice a day in a 28-day cycle, 2-week cycle of 5 days treatment followed by a 2-day rest period, and then a 14-day rest period Bevacizumab: 5mg/kg given intravenously in a 2-week cycle Primary outcome(s): relative dose intensity Study Design: Single arm Non-randomized

DISEASE(S): Metastaic Colorectal Cancer

PROVIDER: 2635519 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2637697 | ecrin-mdr-crc
| 2637698 | ecrin-mdr-crc
| 2636928 | ecrin-mdr-crc
| 2645202 | ecrin-mdr-crc
| 2614211 | ecrin-mdr-crc
| 2610898 | ecrin-mdr-crc
| 2646936 | ecrin-mdr-crc
| 100929 | ecrin-mdr-crc
| 2641267 | ecrin-mdr-crc
| 2628236 | ecrin-mdr-crc